302 Results

People

  1. Motzer
    Motzer
  2. Kris
    Kris
  3. Drilon
    Drilon
  4. Zelenetz
    Zelenetz
  5. Gerecitano
    Gerecitano
  6. Horwitz
    Horwitz
  7. Hudis
    Hudis
  8. Miller
    Miller
  9. Moskowitz
    Moskowitz
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (127)
  3. Hematologic Malignancies, Division of (81)
  4. Center for Hematologic Malignancies (70)
  5. Genitourinary Oncology Service (39)
  6. Epidemiology and Biostatistics (37)
  7. GSK Faculty (35)
  8. Survivorship Research (34)
  9. Biostatistics Service (32)
  10. Radiology, Department of (31)
  1. "coughing"
Formats
  1. Journal Article (285)
  2. Review (7)
  3. Research Letter (5)
  4. Editorial (2)
  5. Conference Paper (1)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (210)
  2. Solid Tumor Oncology Division (127)
  3. Hematologic Malignancies, Division of (81)
  4. Center for Hematologic Malignancies (70)
  5. Genitourinary Oncology Service (39)
  6. Epidemiology and Biostatistics (37)

More Groups

People
  1. Robert Motzer (22)
  2. Mark Kris (12)
  3. Alexander Drilon (9)
  4. Andrew Zelenetz (9)
  5. Clifford Hudis (8)
  6. John Gerecitano (8)

More People

Years
  1. 2025 (9)
  2. 2024 (24)
  3. 2023 (25)
  4. 2022 (18)
  5. 2021 (14)
  6. 2020 (30)

More Years

Publications
  1. Lancet Oncology (23)
  2. Clinical Cancer Research (22)
  3. Journal of Clinical Oncology (16)
  4. New England Journal of Medicine (15)
  5. Blood (13)
  6. Cancer (13)

More Publications

Publishers
  1. Elsevier Inc. (52)
  2. Elsevier Science, Inc. (37)
  3. American Association for Cancer Research (23)
  4. Nature Publishing Group (21)
  5. Wiley Blackwell (18)
  6. American Society of Clinical Oncology (17)

More Publishers

Results (302)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian cancer: A phase I study
    Journal Article

    Konner, J. A.; Bell-Mcguinn, K. M.; Sabbatini, P.; Hensley, M. L.; Tew, W. P.; Pandit-Taskar, N.; Vander Els, N.; Phillips, M. D.; Schweizer, C.; Weil, S. C.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Brain metastases
    Journal Article

    Kamar, F. G.; Posner, J. B.
    Seminars in Neurology (2010)

    Fulltext@MSK | Save
  • Improved survival with ipilimumab in patients with metastatic melanoma
    Journal Article

    Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; more...
    New England Journal of Medicine (2010)

    Fulltext@MSK | Save
  • A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer
    Journal Article

    Haura, E. B.; Ricart, A. D.; Larson, T. G.; Stella, P. J.; Bazhenova, L.; Miller, V. A.; Cohen, R. B.; Eisenberg, P. D.; Selaru, P.; Wilner, K. D.; more...
    Clinical Cancer Research (2010)

    Fulltext@MSK | Save
  • Malignant histiocytoses/disseminated histiocytic sarcoma with hemophagocytic syndrome in a patient with mediastinal germ cell tumor
    Journal Article

    Shinoda, H.; Yoshida, A.; Teruya-Feldstein, J.
    Applied Immunohistochemistry & Molecular Morphology (2009)

    Fulltext@MSK | Save
  • Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study
    Journal Article

    Reece, D. E.; Sanchorawala, V.; Hegenbart, U.; Merlini, G.; Palladini, G.; Fermand, J. P.; Vescio, R. A.; Liu, X.; Elsayed, Y. A.; Cakana, A.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies
    Journal Article

    O'Connor, O. A.; Stewart, A. K.; Vallone, M.; Molineaux, C. J.; Kunkel, L. A.; Gerecitano, J. F.; Orlowski, R. Z.
    Clinical Cancer Research (2009)

    Fulltext@MSK | Save
  • Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial
    Journal Article

    O'Connor, O. A.; Moskowitz, C.; Portlock, C.; Hamlin, P.; Straus, D.; Dumitrescu, O.; Sarasohn, D.; Gonen, M.; Butos, J.; Neylon, E.; more...
    British Journal of Haematology (2009)

    Fulltext@MSK | Save
  • Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma
    Journal Article

    Motzer, R. J.; Feldman, D. R.; Baum, M. S.; Ginsberg, M. S.; Hassoun, H.; Flombaum, C. D.; Velasco, S.; Fischer, P.; Ronnen, E.; Ishill, N.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
    Journal Article

    Meyers, P. A.
    Expert Review of Anticancer Therapy (2009)

    Fulltext@MSK | Save